ICER provides second update to pricing models for remdesivir as a treatment for COVID-19

10 November 2020 - Based on an analysis of four studies evaluating remdesivir’s influence on mortality, ICER has concluded that the ...

Read more →

A health opportunity cost threshold for cost effectiveness analysis in the United State

3 November 2020 - Cost effectiveness analysis is an important tool for informing treatment coverage and pricing decisions, yet no consensus ...

Read more →

Should access to life saving medicines be determined by economic evaluations?

9 January 2020 - Time is the most precious commodity all of us have.  ...

Read more →

Improving transparency in decision models: current issues and potential solutions

23 October 2019 - Decision-analytic models have become an essential tool used to inform health technology assessments. ...

Read more →

A non-inferiority framework for cost-effectiveness analysis

24 July 2019 - Traditional decision rules have limitations when a new technology is less effective and less costly than a ...

Read more →

Novel approaches to value assessment within the cost-effectiveness framework

20 June 2019 - The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis of healthcare interventions ...

Read more →

New cost-effectiveness methods to determine value-based prices for potential cures: what are the options?

12 June 2019 - Evaluating different approaches to assessing the clinical effectiveness and value of potential cures will be essential to ...

Read more →

Incorporating future medical costs: impact on cost-effectiveness analysis in cancer patients

12 June 2019 - The inclusion of future medical costs in cost-effectiveness analyses remains a controversial issue.  ...

Read more →

Cost effectiveness analysis in the context of US commercial health insurance

29 May 2019 - Discussions of the cost effectiveness of medical services often are couched in the framework of a ...

Read more →

Expanding the scope of costs and benefits for economic evaluations in health: some words of caution

18 April 2019 - Discussions regarding the appropriate scope of costs and benefits for inclusion in economic evaluation in healthcare have ...

Read more →

Choosing a time horizon in cost and cost-effectiveness analyses

21 February 2019 - When designing a comparative outcomes or a cost-effectiveness analysis, the time horizon defining the duration of time ...

Read more →

Future costs in cost-effectiveness analyses: past, present, future

23 January 2019 - There has been considerable debate on the extent to which future costs should be included in cost-effectiveness ...

Read more →

Which databases should be used to identify studies for systematic reviews of economic evaluations?

16 November 2018 - This study investigated which databases and which combinations of databases should be used to identify economic evaluations ...

Read more →

Systematic reviews of economic evaluations in health technology assessment: a review of characteristics and applied methods

22 October 2018 - When making decisions in health care, it is essential to consider economic evidence about an intervention.  ...

Read more →

Takeda pioneers NICE’s new service for economic model review

7 June 2018 - NICE Scientific Advice (NSA) launched a new health economic model review service, PRIMA, in December 2017 and ...

Read more →